RET and medullary thyroid gland carcinoma: The identification of activating mutations of the RET tyrosine kinase receptor in both hereditary and sporadic MTC makes this malignancy an excellent model to examine the effect of a group of small organic molecule tyrosine kinase inhibitors (TKIs) for the treatment of metastatic MTC.